Evidence map›Paper›PMID 21233243›Full record

GuidelineJournal of the National Comprehensive Cancer Network : JNCCN2011

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Peter L Greenberg, Eyal Attar, John M Bennett, Clara D Bloomfield, Carlos M De Castro, H Joachim Deeg, James M Foran, Karin Gaensler, Guillermo Garcia-Manero, Steven D Gore and 12 more

Registry-linked trialOpen access · bronzeAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal of the National Comprehensive Cancer Network : JNCCN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05204953 (Mean Platelet Volume and Its Relation to Risk Stratification of Myelodysplastic Syndromes), which is not on this map. Cited by 140 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 4 pooled it
23.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05204953 completednot on this mapstarted 2013, after this paper: background citation

Mean Platelet Volume and Its Relation to Risk Stratification of Myelodysplastic Syndromes

TypeobservationalSponsorAssiut UniversityRan2013 to 2015Enrolled71ConditionsMyelodysplastic Syndromes
3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 4 syntheses or guidelines pooled it, 289 citations in OpenAlex.

  1. Thrombopoietin mimetics for patients with myelodysplastic syndromes.The Cochrane database of systematic reviews · 2017
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
    Trial
  14. Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2013
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Peter L GreenbergStanford Comprehensive Cancer Center , USA.
Eyal Attar
John M Bennett
Clara D Bloomfield
Carlos M De Castro
H Joachim Deeg
James M Foran
Karin Gaensler
Guillermo Garcia-Manero
Steven D Gore
David Head
Rami Komrokji
Lori J Maness
Michael Millenson
Stephen D Nimer
Margaret R O'Donnell
Mark A Schroeder
Paul J Shami
Richard M Stone
James E Thompson
Peter Westervelt
National Comprehensive Cancer Network
University of Utah · USHuntsman Cancer Institute · US

Funding

Targeting Epigenomics in Myeloid NeoplasmsK24CA111717 · NCI · YALE UNIVERSITY · PI GORE, STEVEN D · 2005 to 2015
$1.7M
NCI NIH HHS K24 CA111717
6 · The paper itself

Abstract

These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Four drugs have recently been approved by the FDA for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic abnormalities; azacytidine and decitabine for treating patients with higher-risk or nonresponsive MDS; and deferasirox for iron chelation of iron overloaded patients with MDS. However, because a substantial proportion of patient subsets with MDS lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines for management of thrombocytopenia in MDS needs further evaluation. In addition, further determination of the effects of these therapeutic interventions on the patient's quality of life is important.(116,119,120,128,129) Progress toward improving management of MDS has occurred over the past few years, and more advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials.

Indexed as

Clinical Trials as TopicHumansMyelodysplastic Syndromes

Identifiers

PMID21233243
PMCPMC3768131
OpenAlexW1581590112

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.